Ignyta (RXDX) Appoints Adrian Senderowicz, M.D., As Chief Medical Officer And Senior Vice President, Clinical Development And Regulatory Affairs

Ignyta (RXDX) Appoints Adrian Senderowicz, M.D., As Chief Medical Officer And Senior Vice President, Clinical Development And Regulatory Affairs

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Adrian Senderowicz, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Clinical Development and Regulatory Affairs.

"Adrian's deep experience in clinical, research, development and regulatory affairs in the oncology setting will be extremely valuable to Ignyta," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "His extensive experience in large pharma and biotech, as well as with the FDA and NCI, will make him instrumental to the company's success as we strive to provide new treatment options for patients with our proprietary oncology drug development programs."
 

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.